Biomarkers in dementia [2]

Archives of Neurology

Volumn 64, Issue 9, 2007, Pages 1356-

  Vanacore, Nicola ^a   Galeotti, Francesca ^b   Maggini, Marina ^b   Raschetti, Roberto ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DEMENTIA; HUMAN; LETTER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; CEREBROSPINAL FLUID; METABOLISM; NOTE;

AGED; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; DEMENTIA; HUMANS; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 34548612000     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.9.1356     Document Type: Letter

References (5)

1. 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.
2. Panza F, D'Introno A, Colacicco AM, et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry. 2005;13(8):633-644.
3. Frisoni GB, Canu E, Geroldi C, Zanetti O, Zacchi V. Drug prescription in mild cognitive impairment: the physicians' perspective in Italy. Int J Geriatr Psychiatry. 2006;21(11):1071-1077.
4. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev. 2006;(3):CD006104.
5. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;(1):CD001747.